Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lexeo Therapeutics, Inc. Common Stock (LXEO)
USD4.70
+0.08 (+1.62%)
US NASDAQ Healthcare Biotechnology
Address
345 Park Avenue South 10010
New York City, US
New York City, US
CEO
R. Nolan Townsend
Website
lexeotx.com
IPO
2023-11-03
CIK 1907108 ISIN US52886X1072
Description
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.70
+0.08 (+1.62%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
897.1K
Beta
1.39
Float Shares
41.44M
Free Float %
55.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.97% | -1.13% | +2.34% | -6.85% | -33.55% | -38.37% | +132.70% | -39.10% | -39.10% | -39.10% | -39.10% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
4.70
Low
10.00
+113.0%
Consensus
18.50
+294.0%
Median
19.50
+315.3%
High
25.00
+432.5%
DCF (Unlevered)
0.95
-79.9%
DCF (Levered)
1.03
-78.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 9 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 9 |
18.78
+300.0%
|
| All Time | 10 |
19.70
+319.6%
|
Quality scores
Altman Z-Score
11.51
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+39.8% ★ Q1'26: +74.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-137.1% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+68.8% Q1'26: +145.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.08×
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 EPS Ana. |
Dec 2027 5 Rev. Ana. 6 EPS Ana. |
Dec 2028 5 Rev. Ana. 4 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 4.50M (-100.0%)
|
—
est: 1.13M (-100.0%)
|
—
— – —
-100.0% YoY
|
9.86M
9.86M – 9.86M
|
92.50M
92.50M – 92.50M
+838.4% YoY
|
300.32M
300.32M – 300.32M
+224.7% YoY
|
589.30M
589.30M – 589.30M
+96.2% YoY
|
| EBITDA |
-96.19M
est: 900.0K (-10,788.2%)
|
-97.68M
est: 225.0K (-43,511.7%)
|
—
— – —
-100.0% YoY
|
1.97M
1.97M – 1.97M
|
18.50M
18.50M – 18.50M
+838.4% YoY
|
60.06M
60.06M – 60.06M
+224.7% YoY
|
117.86M
117.86M – 117.86M
+96.2% YoY
|
| EBIT |
-98.20M
est: 900.0K (-11,010.7%)
|
-99.76M
est: 225.0K (-44,435.8%)
|
—
— – —
-100.0% YoY
|
1.97M
1.97M – 1.97M
|
18.50M
18.50M – 18.50M
+838.4% YoY
|
60.06M
60.06M – 60.06M
+224.7% YoY
|
117.86M
117.86M – 117.86M
+96.2% YoY
|
| Net Income |
-98.33M
est: -168.98M (+41.8%)
|
-99.96M
est: -99.96M (+0.0%)
|
-66.99M
-79.79M – -54.20M
+33.0% YoY
|
-60.22M
-76.59M – -43.84M
+10.1% YoY
|
-33.03M
-77.80M – 11.74M
+45.2% YoY
|
37.98M
37.98M – 37.98M
+215.0% YoY
|
160.72M
160.72M – 160.72M
+323.2% YoY
|
| SGA |
31.68M
est: 23.11M (+37.1%)
|
45.46M
est: 5.78M (+686.8%)
|
—
— – —
-100.0% YoY
|
50.62M
50.62M – 50.62M
|
475.05M
475.05M – 475.05M
+838.4% YoY
|
1.54B
1.54B – 1.54B
+224.7% YoY
|
3.03B
3.03B – 3.03B
+96.2% YoY
|
| EPS |
-3.09
est: -3.12 (+1.0%)
|
-1.86
est: -1.95 (+4.4%)
|
-1.19
-1.49 – -1.01
+38.9% YoY
|
-1.27
-1.43 – -0.82
-7.1% YoY
|
-0.72
-1.45 – 0.22
+43.4% YoY
|
0.71
0.71 – 0.71
+198.3% YoY
|
3.00
3.00 – 3.00
+323.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-98.56M
OE per share TTM
-2.03
Owner's Yield
-22.14%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1,612.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
34
Total invested
15.38M
Insider transactions (90d)
1
Beneficial owners (>5%)
23
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Eventide Asset Management, LLC | 3.00M | 11.93% | 3.00M | — | 3.00M | — | IA | Delaware | 2023-12-11 | ↗ |
| 2 | Finny Kuruvilla, M.D. Ph. D. | 3.00M | 11.93% | — | 3.00M | — | — | HC, IN | United States | 2023-12-11 | ↗ |
| 3 | Robin C. John | 3.00M | 11.93% | — | 3.00M | — | — | HC, IN | United States | 2023-12-11 | ↗ |
| 4 | Adage Capital Management, L.P. | 2.60M | 7.86% | — | 2.60M | — | — | IA, PN | Delaware | 2024-11-12 | ↗ |
| 5 | Phillip Gross | 2.60M | 7.86% | — | 2.60M | — | — | HC, IN | Delaware | 2024-11-12 | ↗ |
| 6 | Robert Atchinson | 2.60M | 7.86% | — | 2.60M | — | — | HC, IN | Delaware | 2024-11-12 | ↗ |
| 7 | Juliet Tammenoms Bakker | 2.57M | 9.60% | — | 2.57M | — | 2.57M | IN | — | 2024-02-13 | ↗ |
| 8 | Longitude Capital Partners IV, LLC | 2.57M | 9.60% | — | 2.57M | — | 2.57M | OO | — | 2024-02-13 | ↗ |
| 9 | Longitude Venture Partners IV, L.P. | 2.57M | 9.60% | — | 2.57M | — | 2.57M | PN | — | 2024-02-13 | ↗ |
| 10 | Patrick G. Enright | 2.57M | 9.60% | — | 2.57M | — | 2.57M | IN | — | 2024-02-13 | ↗ |
| 11 | D1 Capital Partners L.P. | 2.51M | 9.40% | — | 2.51M | — | — | IA, PN | Delaware | 2024-02-14 | ↗ |
| 12 | Daniel Sundheim | 2.51M | 9.40% | — | 2.51M | — | — | HC, IN | United States of America | 2024-02-14 | ↗ |
| 13 | EIN #00-0000000 | 2.33M | 8.70% | — | 2.33M | — | 2.33M | IA, HC | Jersey, Channel Islands | 2024-02-14 | ↗ |
| 14 | Anne-Mari Paster | 2.16M | 8.10% | — | 2.16M | — | — | IN | Cayman Islands | 2024-02-14 | ↗ |
| 15 | Claudio Nessi | 2.16M | 8.10% | — | 2.16M | — | — | IN | Cayman Islands | 2024-02-14 | ↗ |
| 16 | Omega Fund VI GP Manager, Ltd. | 2.16M | 8.10% | — | 2.16M | — | — | PN | Cayman Islands | 2024-02-14 | ↗ |
| 17 | Omega Fund VI GP, L.P. | 2.16M | 8.10% | — | 2.16M | — | — | PN | Cayman Islands | 2024-02-14 | ↗ |
| 18 | Omega Fund VI, L.P. | 2.16M | 8.10% | — | 2.16M | — | — | PN | Cayman Islands | 2024-02-14 | ↗ |
| 19 | Otello Stampacchia | 2.16M | 8.10% | — | 2.16M | — | — | IN | Cayman Islands | 2024-02-14 | ↗ |
| 20 | Lene Skole | 1.84M | 6.90% | 1.84M | — | 1.84M | — | IN | Denmark | 2024-02-14 | ↗ |
| 21 | Lundbeckfond Invest A/S | 1.84M | 6.90% | 1.84M | — | 1.84M | — | CO | Denmark | 2024-02-14 | ↗ |
| 22 | Novo Holdings A/S | 1.29M | 5.10% | 1.29M | — | 1.29M | — | CO | Denmark | 2023-11-24 | ↗ |
| 23 | 2. | 10.00 | 8.30% | — | 2.08M | — | — | HC, OO | Delaware | 2023-11-17 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
34
-112 vs prev Q
New positions
4
Closed positions
114
Increased
19
Reduced
9
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 175.0K +175.0K (+100.0%) | 1.74B +1.7B (+100.0%) | 0.29% +0.287 pp | 0.57% +0.574 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 2 | JANUS HENDERSON GROUP PLC | 5.51M -595.9K (-9.8%) | 54.67M +14.2M (+35.0%) | 9.04% -0.977 pp | 0.02% +0.006 pp | USD9.82 +1.1% | 9 qtrs — |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 5.00M +5.0M (+100.0%) | 49.65M +49.7M (+100.0%) | 8.20% +8.199 pp | 0.51% +0.509 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 4 | BLACKROCK, INC. | 4.91M +2.7M (+126.0%) | 48.73M +34.3M (+238.0%) | 8.05% +4.487 pp | 0.00% +0.001 pp | USD9.25 +7.4% | 6 qtrs — |
| 5 | PARADIGM BIOCAPITAL ADVISORS LP | 4.76M +4.8M (+100.0%) | 47.30M +47.3M (+100.0%) | 7.81% +7.811 pp | 1.21% +1.207 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 6 | VESTAL POINT CAPITAL, LP | 4.48M +1.2M (+37.7%) | 44.44M +22.9M (+105.9%) | 7.34% +2.009 pp | 1.51% +0.536 pp | USD7.92 +25.4% | 8 qtrs — |
| 7 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 4.42M +— (+0.0%) | 43.94M +14.6M (+49.5%) | 7.26% +0.000 pp | 1.18% +0.300 pp | USD5.10 +94.7% | 6 qtrs — |
| 8 | VANGUARD GROUP INC | 3.89M +1.7M (+74.9%) | 38.67M +23.9M (+161.6%) | 6.39% +2.735 pp | 0.00% +0.000 pp | USD8.78 +13.1% | 9 qtrs — |
| 9 | CITADEL ADVISORS LLC | 3.77M +55.3K (+1.5%) | 37.48M +12.8M (+51.8%) | 6.19% +0.091 pp | 0.01% +0.002 pp | USD11.08 -10.4% | 9 qtrs — |
| 10 | AVORO CAPITAL ADVISORS LLC | 3.30M +3.3M (+100.0%) | 32.77M +32.8M (+100.0%) | 5.41% +5.412 pp | 0.32% +0.315 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 11 | AFFINITY ASSET ADVISORS, LLC | 3.20M -670.5K (-17.3%) | 31.78M +6.1M (+23.6%) | 5.25% -1.100 pp | 1.81% -0.428 pp | USD4.00 +148.3% | 4 qtrs — |
| 12 | WOODLINE PARTNERS LP | 3.20M +625.6K (+24.3%) | 31.75M +14.7M (+85.9%) | 5.24% +1.026 pp | 0.12% +0.043 pp | USD8.14 +22.0% | 8 qtrs — |
| 13 | STATE STREET CORP | 3.19M +2.6M (+485.1%) | 31.65M +28.0M (+775.0%) | 5.23% +4.334 pp | 0.00% +0.001 pp | USD9.92 +0.1% | 8 qtrs — |
| 14 | ORBIMED ADVISORS LLC | 2.13M +2.1M (+100.0%) | 21.10M +21.1M (+100.0%) | 3.48% +3.485 pp | 0.43% +0.433 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 15 | POINT72 ASSET MANAGEMENT, L.P. | 1.89M -47.1K (-2.4%) | 18.81M +5.9M (+45.9%) | 3.11% -0.077 pp | 0.02% -0.001 pp | USD6.57 +51.1% | 6 qtrs — |
| 16 | OCTAGON CAPITAL ADVISORS LP | 1.73M +1.7M (+100.0%) | 17.13M +17.1M (+100.0%) | 2.83% +2.829 pp | 2.08% +2.080 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 17 | BALYASNY ASSET MANAGEMENT L.P. | 1.64M -2.3M (-58.2%) | 16.24M -9.8M (-37.5%) | 2.68% -3.737 pp | 0.02% -0.012 pp | USD4.02 +147.0% | 3 qtrs — |
| 18 | GEODE CAPITAL MANAGEMENT, LLC | 1.45M +724.0K (+100.3%) | 14.36M +9.6M (+199.5%) | 2.37% +1.187 pp | 0.00% +0.001 pp | USD10.35 -4.1% | 9 qtrs — |
| 19 | ADAR1 CAPITAL MANAGEMENT, LLC | 1.39M -138.8K (-9.1%) | 13.83M +3.7M (+36.0%) | 2.28% -0.228 pp | 1.02% +0.061 pp | USD6.72 +47.8% | 7 qtrs — |
| 20 | SUVRETTA CAPITAL MANAGEMENT, LLC | 1.25M +1.3M (+100.0%) | 12.41M +12.4M (+100.0%) | 2.05% +2.050 pp | 0.25% +0.254 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 21 | 683 CAPITAL MANAGEMENT, LLC | 1.12M +197.3K (+21.4%) | 11.12M +5.0M (+81.5%) | 1.84% +0.324 pp | 0.48% +0.164 pp | USD7.22 +37.5% | 2 qtrs — |
| 22 | NANTAHALA CAPITAL MANAGEMENT, LLC | 1.00M +1.0M (+100.0%) | 9.93M +9.9M (+100.0%) | 1.64% +1.640 pp | 0.33% +0.328 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 23 | MILLENNIUM MANAGEMENT LLC | 908.0K -1.4M (-60.8%) | 9.02M -6.3M (-41.3%) | 1.49% -2.305 pp | 0.00% -0.003 pp | USD4.09 +142.8% | 9 qtrs — |
| 24 | BLACKSTONE INC. | 905.0K -220.0K (-19.6%) | 8.99M +1.5M (+20.3%) | 1.48% -0.361 pp | 0.04% +0.005 pp | USD12.29 -19.2% | 9 qtrs — |
| 25 | DIMENSIONAL FUND ADVISORS LP | 862.9K -49.6K (-5.4%) | 8.57M +2.5M (+41.4%) | 1.42% -0.081 pp | 0.00% +0.001 pp | USD6.50 +52.8% | 3 qtrs — |
| 26 | GOLDMAN SACHS GROUP INC | 781.9K +639.5K (+449.0%) | 7.76M +6.8M (+721.1%) | 1.28% +1.049 pp | 0.00% +0.001 pp | USD9.52 +4.3% | 8 qtrs — |
| 27 | SIREN, L.L.C. | 720.6K +117.2K (+19.4%) | 7.16M +3.1M (+78.6%) | 1.18% +0.192 pp | 0.21% +0.057 pp | USD9.18 +8.2% | 6 qtrs — |
| 28 | SILVERARC CAPITAL MANAGEMENT, LLC | 617.6K -161.0K (-20.7%) | 6.13M +962.9K (+18.6%) | 1.01% -0.264 pp | 0.85% +0.155 pp | USD6.64 +49.5% | 2 qtrs — |
| 29 | IKARIAN CAPITAL, LLC | 513.0K -54.6K (-9.6%) | 5.09M +1.3M (+35.2%) | 0.84% -0.090 pp | 0.40% +0.017 pp | USD7.42 +33.8% | 6 qtrs — |
| 30 | D. E. SHAW & CO., INC. | 480.2K +467.4K (+3,646.3%) | 4.77M +4.7M (+5,502.5%) | 0.79% +0.766 pp | 0.00% +0.003 pp | USD9.84 +0.9% | 2 qtrs — |
| 31 | INVESCO LTD. | 463.0K +463.0K (+100.0%) | 4.60M +4.6M (+100.0%) | 0.76% +0.759 pp | 0.00% +0.001 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 32 | NORTHERN TRUST CORP | 457.1K +220.6K (+93.3%) | 4.54M +3.0M (+189.1%) | 0.75% +0.362 pp | 0.00% +0.000 pp | USD10.45 -5.0% | 9 qtrs — |
| 33 | VERITION FUND MANAGEMENT LLC | 428.5K +13.6K (+3.3%) | 4.25M +1.5M (+54.4%) | 0.70% +0.022 pp | 0.02% +0.005 pp | USD12.35 -19.6% | 9 qtrs — |
| 34 | TWO SIGMA INVESTMENTS, LP | 400.6K +315.8K (+372.6%) | 3.98M +3.4M (+606.7%) | 0.66% +0.518 pp | 0.01% +0.005 pp | USD8.73 +13.7% | 4 qtrs — |
| 35 | DAFNA CAPITAL MANAGEMENT LLC | 340.9K -17.2K (-4.8%) | 3.38M +1.0M (+42.4%) | 0.56% -0.028 pp | 0.79% +0.199 pp | USD8.15 +21.8% | 6 qtrs — |
| 36 | AQR CAPITAL MANAGEMENT LLC | 337.4K -10.5K (-3.0%) | 3.35M +1.0M (+45.0%) | 0.55% -0.017 pp | 0.00% +0.000 pp | USD5.24 +89.5% | 5 qtrs — |
| 37 | UBS GROUP AG | 281.1K +31.2K (+12.5%) | 2.79M +1.1M (+68.2%) | 0.46% +0.051 pp | 0.00% +0.000 pp | USD5.04 +97.0% | 8 qtrs — |
| 38 | BNP PARIBAS ARBITRAGE, SNC | 257.4K +226.7K (+737.8%) | 2.56M +2.4M (+1,152.8%) | 0.42% +0.372 pp | 0.00% +0.001 pp | USD9.50 +4.5% | 8 qtrs — |
| 39 | AMERIPRISE FINANCIAL INC | 243.3K +76.8K (+46.1%) | 2.42M +1.3M (+118.5%) | 0.40% +0.126 pp | 0.00% +0.000 pp | USD7.68 +29.3% | 2 qtrs — |
| 40 | Y-INTERCEPT (HONG KONG) LTD | 231.2K +231.2K (+100.0%) | 2.30M +2.3M (+100.0%) | 0.38% +0.379 pp | 0.05% +0.051 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 41 | RENAISSANCE TECHNOLOGIES LLC | 217.8K +68.5K (+45.9%) | 2.16M +1.2M (+118.1%) | 0.36% +0.112 pp | 0.00% +0.002 pp | USD6.35 +56.4% | 4 qtrs — |
| 42 | NUVEEN, LLC | 211.5K +178.4K (+539.0%) | 2.10M +1.9M (+855.6%) | 0.35% +0.293 pp | 0.00% +0.001 pp | USD8.92 +11.3% | 4 qtrs — |
| 43 | PRIVIUM FUND MANAGEMENT B.V. | 192.6K +194.0 (+0.1%) | 1.91M +634.8K (+49.7%) | 0.32% +0.000 pp | 0.35% +0.122 pp | USD5.99 +65.8% | 5 qtrs — |
| 44 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 192.2K +86.5K (+81.7%) | 1.91M +1.2M (+171.8%) | 0.32% +0.142 pp | 0.00% +0.000 pp | USD9.67 +2.7% | 8 qtrs — |
| 45 | BARCLAYS PLC | 188.8K +138.5K (+275.9%) | 1.87M +1.4M (+312.9%) | 0.31% +0.194 pp | 0.00% +0.000 pp | USD9.06 +9.6% | 9 qtrs — |
| 46 | BANK OF NEW YORK MELLON CORP | 166.7K +95.1K (+132.6%) | 1.66M +1.2M (+247.9%) | 0.27% +0.156 pp | 0.00% +0.000 pp | USD10.07 -1.4% | 9 qtrs — |
| 47 | BANK OF AMERICA CORP /DE/ | 160.3K +132.0K (+466.8%) | 1.59M +1.4M (+747.7%) | 0.26% +0.198 pp | 0.00% +0.000 pp | USD9.89 +0.4% | 9 qtrs — |
| 48 | MORGAN STANLEY | 140.2K +42.1K (+43.0%) | 1.39M +740.9K (+113.8%) | 0.23% +0.069 pp | 0.00% +0.000 pp | USD8.83 +12.5% | 9 qtrs — |
| 49 | JANE STREET GROUP, LLC | 140.1K +10.6K (+8.2%) | 1.39M +531.5K (+61.8%) | 0.23% +0.017 pp | 0.00% +0.000 pp | USD6.89 +44.1% | 2 qtrs — |
| 50 | PERCEPTIVE ADVISORS LLC | 139.8K +— (+0.0%) | 1.39M +460.1K (+49.5%) | 0.23% +0.000 pp | 0.02% -0.002 pp | USD9.04 +9.8% | 6 qtrs — |
| 51 | BOOTHBAY FUND MANAGEMENT, LLC | 136.4K -44.4K (-24.5%) | 1.35M +154.1K (+12.8%) | 0.22% -0.073 pp | 0.02% +0.003 pp | USD7.78 +27.6% | 6 qtrs — |
| 52 | QUBE RESEARCH & TECHNOLOGIES LTD | 133.3K +133.3K (+100.0%) | 1.32M +1.3M (+100.0%) | 0.22% +0.219 pp | 0.00% +0.001 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 53 | BURKEHILL GLOBAL MANAGEMENT, LP | 125.0K +125.0K (+100.0%) | 1.24M +1.2M (+100.0%) | 0.21% +0.205 pp | 0.08% +0.082 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 54 | RAFFERTY ASSET MANAGEMENT, LLC | 102.2K +102.2K (+100.0%) | 1.01M +1.0M (+100.0%) | 0.17% +0.168 pp | 0.00% +0.004 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 55 | SQUAREPOINT OPS LLC | 92.6K +92.6K (+100.0%) | 919.6K +919.6K (+100.0%) | 0.15% +0.152 pp | 0.00% +0.001 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 56 | WELLINGTON MANAGEMENT GROUP LLP | 83.2K +83.2K (+100.0%) | 826.5K +826.5K (+100.0%) | 0.14% +0.137 pp | 0.00% +0.000 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 57 | TWO SIGMA ADVISERS, LP | 81.3K +81.3K (+100.0%) | 807.3K +807.3K (+100.0%) | 0.13% +0.133 pp | 0.00% +0.002 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 58 | WELLS FARGO & COMPANY/MN | 70.7K +51.5K (+267.2%) | 702.4K +574.5K (+449.2%) | 0.12% +0.084 pp | 0.00% +0.000 pp | USD9.45 +5.1% | 9 qtrs — |
| 59 | RHUMBLINE ADVISERS | 69.4K +37.6K (+118.4%) | 688.8K +477.9K (+226.6%) | 0.11% +0.062 pp | 0.00% +0.000 pp | USD10.14 -2.1% | 8 qtrs — |
| 60 | ATOM INVESTORS LP | 68.5K +68.5K (+100.0%) | 680.1K +680.1K (+100.0%) | 0.11% +0.112 pp | 0.05% +0.054 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 61 | ALLIANCEBERNSTEIN L.P. | 61.8K +32.4K (+110.5%) | 613.8K +418.8K (+214.7%) | 0.10% +0.053 pp | 0.00% +0.000 pp | USD9.56 +3.9% | 7 qtrs — |
| 62 | DEUTSCHE BANK AG\ | 57.2K +32.8K (+135.0%) | 567.7K +406.2K (+251.5%) | 0.09% +0.054 pp | 0.00% +0.000 pp | USD8.57 +15.9% | 7 qtrs — |
| 63 | ACADIAN ASSET MANAGEMENT LLC | 50.9K +50.9K (+100.0%) | 505.0K +505.0K (+100.0%) | 0.08% +0.084 pp | 0.00% +0.001 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 64 | AMERICAN CENTURY COMPANIES INC | 46.0K +9.8K (+27.2%) | 456.7K +216.6K (+90.2%) | 0.08% +0.016 pp | 0.00% +0.000 pp | USD7.34 +35.3% | 2 qtrs — |
| 65 | PROFUND ADVISORS LLC | 38.1K +38.1K (+100.0%) | 377.9K +377.9K (+100.0%) | 0.06% +0.062 pp | 0.01% +0.012 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 66 | METLIFE INVESTMENT MANAGEMENT, LLC | 35.7K +35.7K (+100.0%) | 354.7K +354.7K (+100.0%) | 0.06% +0.059 pp | 0.00% +0.002 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 67 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 35.3K +23.8K (+207.8%) | 349.0K +272.9K (+358.9%) | 0.06% +0.039 pp | 0.00% +0.000 pp | USD10.27 -3.3% | 7 qtrs — |
| 68 | PANAGORA ASSET MANAGEMENT INC | 34.3K +— (+0.0%) | 340.6K +112.8K (+49.5%) | 0.06% +0.000 pp | 0.00% +0.000 pp | USD3.47 +186.2% | 4 qtrs — |
| 69 | PRICE T ROWE ASSOCIATES INC /MD/ | 33.9K +21.9K (+183.1%) | 337.0K +257.0K (+321.3%) | 0.06% +0.036 pp | 0.00% +0.000 pp | USD8.75 +13.5% | 5 qtrs — |
| 70 | GRAHAM CAPITAL MANAGEMENT, L.P. | 32.9K +32.9K (+100.0%) | 326.7K +326.7K (+100.0%) | 0.05% +0.054 pp | 0.01% +0.008 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 71 | JPMORGAN CHASE & CO | 29.9K +15.5K (+108.0%) | 296.5K +201.2K (+211.0%) | 0.05% +0.016 pp | 0.00% +0.000 pp | USD10.11 -1.8% | 9 qtrs — |
| 72 | VIRTUS INVESTMENT ADVISERS, INC. | 27.2K +27.2K (+100.0%) | 270.4K +270.4K (+100.0%) | 0.04% +0.045 pp | 0.07% +0.074 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 73 | WINTON GROUP LTD | 26.9K +26.9K (+100.0%) | 267.1K +267.1K (+100.0%) | 0.04% +0.044 pp | 0.01% +0.009 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 74 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 26.2K +3.3K (+14.4%) | 260.2K +108.1K (+71.1%) | 0.04% +0.005 pp | 0.00% +0.002 pp | USD4.83 +105.6% | 3 qtrs — |
| 75 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 26.2K +26.2K (+100.0%) | 251.9K +251.9K (+100.0%) | 0.04% +0.043 pp | 0.00% +0.000 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 76 | IEQ CAPITAL, LLC | 24.7K -8.9K (-26.5%) | 245.2K +22.2K (+10.0%) | 0.04% -0.015 pp | 0.00% +0.000 pp | USD5.72 +73.6% | 3 qtrs — |
| 77 | CERITY PARTNERS LLC | 22.4K -1.2K (-4.9%) | 222.8K +66.2K (+42.3%) | 0.04% -0.002 pp | 0.00% +0.000 pp | USD5.26 +88.8% | 3 qtrs — |
| 78 | PALE FIRE CAPITAL SE | 22.3K -11.3K (-33.7%) | 221.5K -2.0K (-0.9%) | 0.04% -0.019 pp | 0.01% -0.010 pp | USD5.67 +75.1% | 5 qtrs — |
| 79 | OMERS ADMINISTRATION CORP | 20.9K +20.9K (+100.0%) | 207.5K +207.5K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.002 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 80 | SOLTIS INVESTMENT ADVISORS LLC | 20.0K +— (+0.0%) | 198.6K +65.8K (+49.5%) | 0.03% +0.000 pp | 0.01% +0.004 pp | USD3.47 +186.2% | 4 qtrs — |
| 81 | NEW YORK STATE COMMON RETIREMENT FUND | 19.9K +15.7K (+375.0%) | 197.5K +169.7K (+610.3%) | 0.03% +0.026 pp | 0.00% +0.000 pp | USD11.18 -11.2% | 8 qtrs — |
| 82 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 19.1K +19.1K (+100.0%) | 190.1K +190.1K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.000 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 83 | CWM, LLC | 19.0K +89.0 (+0.5%) | 188.0K +63.0K (+50.4%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD5.23 +89.9% | 5 qtrs — |
| 84 | SG AMERICAS SECURITIES, LLC | 18.6K +18.6K (+100.0%) | 185.0K +185.0K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.000 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 85 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 16.4K -159.0 (-1.0%) | 163.2K +53.0K (+48.1%) | 0.03% 0.000 pp | 0.00% +0.001 pp | USD4.27 +132.6% | 3 qtrs — |
| 86 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 16.4K +10.3K (+171.1%) | 162.6K +122.5K (+305.4%) | 0.03% +0.017 pp | 0.00% +0.001 pp | USD8.69 +14.3% | 5 qtrs — |
| 87 | PERSISTENT ASSET PARTNERS LTD | 16.0K +16.0K (+100.0%) | 159.1K +159.1K (+100.0%) | 0.03% +0.026 pp | 0.07% +0.072 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 88 | CITIGROUP INC | 15.3K +7.9K (+105.8%) | 151.9K +102.5K (+207.7%) | 0.03% +0.013 pp | 0.00% +0.000 pp | USD10.40 -4.5% | 9 qtrs — |
| 89 | PROSHARE ADVISORS LLC | 14.8K +14.8K (+100.0%) | 146.5K +146.5K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.000 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 90 | INTECH INVESTMENT MANAGEMENT LLC | 14.2K +2.3K (+19.5%) | 140.9K +62.1K (+78.7%) | 0.02% +0.004 pp | 0.00% +0.001 pp | USD6.76 +46.9% | 5 qtrs — |
| 91 | CAXTON CORP | 13.9K -3.4K (-19.6%) | 138.5K +23.4K (+20.3%) | 0.02% -0.006 pp | 3.24% +2.732 pp | USD14.34 -30.8% | 9 qtrs — |
| 92 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 14.3K +86.0 (+0.6%) | 136.3K +17.5K (+14.7%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD6.66 +49.1% | 2 qtrs — |
| 93 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 13.4K -35.0K (-72.3%) | 133.1K -188.3K (-58.6%) | 0.02% -0.057 pp | 0.00% -0.004 pp | USD5.86 +69.5% | 5 qtrs — |
| 94 | FMR LLC | 13.4K -45.0 (-0.3%) | 132.9K +43.7K (+49.0%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD4.58 +116.8% | 8 qtrs — |
| 95 | SIMPLEX TRADING, LLC | 13.0K +12.5K (+2,511.4%) | 129.4K +126.4K (+4,213.2%) | 0.02% +0.021 pp | 0.00% +0.000 pp | USD9.80 +1.3% | 2 qtrs — |
| 96 | RAYMOND JAMES FINANCIAL INC | 12.5K +12.5K (+100.0%) | 124.5K +124.5K (+100.0%) | 0.02% +0.021 pp | 0.00% +0.000 pp | USD9.93 +0.0% | 1 qtrs NEW |
| 97 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 12.1K -800.0 (-6.2%) | 120.2K +34.5K (+40.3%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD6.64 +49.5% | 4 qtrs — |
| 98 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 11.9K +2.4K (+25.6%) | 118.1K +55.2K (+87.9%) | 0.02% +0.004 pp | 0.01% +0.004 pp | USD7.27 +36.6% | 5 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 72 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.68% | 390.8K | 0.65% |
| 2 | State Street SPDR S&P Biotech ETF XBI | 0.11% | 11.74M | 0.35% |
| 3 | Global X - S&P Biotech ETF CURE.AX | 0.11% | 37.8K | 0.45% |
| 4 | State Street SPDR S&P Kensho New Economies Composite ETF KOMP | 0.10% | 2.72M | 0.20% |
| 5 | Vanguard U.S. Momentum Factor ETF VFMO | 0.08% | 1.42M | 0.13% |
| 6 | iShares Micro-Cap ETF IWC | 0.08% | 1.15M | 0.60% |
| 7 | Vanguard Global Momentum Factor ETF VMO.TO | 0.04% | 153.7K | 0.38% |
| 8 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.03% | 120.3K | 0.40% |
| 9 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.03% | 19.4K | 0.19% |
| 10 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.03% | 19.0K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
0.91
Neutral
Buys
1
Sells
1
Shares acquired
50.0K
Shares disposed
55.0K
Cash buys
—
Cash sales
1.00
Net activity
-5,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-28 | Sepp-Lorenzino Laura | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 5.81 | 290.5K | 50,000 | D | ↗ |
| 2026-04-06 | Townsend Richard Nolan | Director / Officer | S-Sale | D | Common Stock | 55,000 | 5.69 | 313.1K | 340,106 | D | ↗ |
| 2026-03-13 | Townsend Richard Nolan | Director / Officer | A-Award | A | Common Stock | 2,623 | 2.64 | 6.9K | 395,106 | D | ↗ |
| 2026-03-13 | Otero Jose Manuel | Officer | A-Award | A | Common Stock | 5,930 | 2.64 | 15.7K | 131,390 | D | ↗ |
| 2026-02-18 | Townsend Richard Nolan | Director / Officer | S-Sale | D | Common Stock | 10,173 | 6.38 | 64.9K | 392,483 | D | ↗ |
| 2026-02-18 | Otero Jose Manuel | Officer | S-Sale | D | Common Stock | 3,016 | 6.40 | 19.3K | 125,460 | D | ↗ |
| 2026-02-13 | Bhalla Narinder Pal | Officer | A-Award | A | Stock Option (right to buy) | 297,000 | 6.31 | 1.87M | 297,000 | D | ↗ |
| 2026-02-04 | Townsend Richard Nolan | Director / Officer | A-Award | A | Common Stock | 161,665 | 0.00 | — | 402,656 | D | ↗ |
| 2026-02-04 | Tamayo Louis Edward | Officer | A-Award | A | Common Stock | 44,665 | 0.00 | — | 89,665 | D | ↗ |
| 2026-02-04 | Otero Jose Manuel | Officer | A-Award | A | Stock Option (right to buy) | 260,000 | 7.27 | 1.89M | 260,000 | D | ↗ |
| 2026-01-20 | Bhalla Narinder Pal | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-11-18 | Townsend Richard Nolan | Director / Officer | S-Sale | D | Common Stock | 1,127 | 9.27 | 10.4K | 240,991 | D | ↗ |
| 2025-11-18 | See Tai Sandi | Officer | S-Sale | D | Common Stock | 386 | 9.27 | 3.6K | 65,476 | D | ↗ |
| 2025-11-18 | Robertson Jenny | Officer | S-Sale | D | Common Stock | 549 | 9.27 | 5.1K | 68,381 | D | ↗ |
| 2025-11-18 | Otero Jose Manuel | Officer | S-Sale | D | Common Stock | 721 | 9.27 | 6.7K | 63,476 | D | ↗ |
| 2025-11-18 | Adler Eric | Officer | S-Sale | D | Common Stock | 615 | 9.27 | 5.7K | 72,646 | D | ↗ |
| 2025-10-17 | Townsend Richard Nolan | Director / Officer | S-Sale | D | Common Stock | 148 | 9.56 | 1.4K | 242,118 | D | ↗ |
| 2025-10-17 | See Tai Sandi | Officer | S-Sale | D | Common Stock | 44 | 9.56 | 420.68 | 65,862 | D | ↗ |
| 2025-10-17 | Robertson Jenny | Officer | S-Sale | D | Common Stock | 40 | 9.56 | 382.44 | 68,930 | D | ↗ |
| 2025-10-17 | Otero Jose Manuel | Officer | S-Sale | D | Common Stock | 24 | 9.56 | 229.46 | 64,197 | D | ↗ |
| 2025-10-17 | Adler Eric | Officer | S-Sale | D | Common Stock | 38 | 9.56 | 363.32 | 73,261 | D | ↗ |
| 2025-10-15 | Townsend Richard Nolan | Director / Officer | A-Award | A | Common Stock | 33,000 | 0.00 | — | 255,251 | D | ↗ |
| 2025-10-15 | See Tai Sandi | Officer | A-Award | A | Common Stock | 10,890 | 0.00 | — | 69,750 | D | ↗ |
| 2025-10-15 | Robertson Jenny | Officer | A-Award | A | Common Stock | 9,900 | 0.00 | — | 72,456 | D | ↗ |
| 2025-10-15 | Otero Jose Manuel | Officer | A-Award | A | Common Stock | 5,940 | 0.00 | — | 66,312 | D | ↗ |
| 2025-10-15 | Adler Eric | Officer | A-Award | A | Common Stock | 9,570 | 0.00 | — | 76,643 | D | ↗ |
| 2025-09-12 | Townsend Richard Nolan | Director / Officer | A-Award | A | Common Stock | 2,193 | 2.64 | 5.8K | 222,251 | D | ↗ |
| 2025-08-29 | Tamayo Louis Edward | Officer | A-Award | A | Stock Option (right to buy) | 280,000 | 4.79 | 1.34M | 280,000 | D | ↗ |
| 2025-08-18 | Townsend Richard Nolan | Director / Officer | S-Sale | D | Common Stock | 2,735 | 4.67 | 12.8K | 220,058 | D | ↗ |
| 2025-08-18 | See Tai Sandi | Officer | S-Sale | D | Common Stock | 382 | 4.67 | 1.8K | 58,860 | D | ↗ |
| 2025-08-18 | Robertson Jenny | Officer | S-Sale | D | Common Stock | 542 | 4.67 | 2.5K | 62,556 | D | ↗ |
| 2025-08-18 | Otero Jose Manuel | Officer | S-Sale | D | Common Stock | 2,848 | 4.67 | 13.3K | 60,372 | D | ↗ |
| 2025-08-18 | Adler Eric | Officer | S-Sale | D | Common Stock | 608 | 4.67 | 2.8K | 67,073 | D | ↗ |
| 2025-08-15 | Tamayo Louis Edward | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-26 | Van Hauwermeiren Timothy | Director | A-Award | A | Stock Option (right to buy) | 22,916 | 4.18 | 95.8K | 22,916 | D | ↗ |
| 2025-06-26 | Tanguler Tolga | Director | A-Award | A | Stock Option (right to buy) | 14,583 | 4.18 | 61.0K | 14,583 | D | ↗ |
| 2025-06-26 | DIAZ REINALDO M | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.18 | 104.5K | 25,000 | D | ↗ |
| 2025-06-26 | COOPERSTONE BRENDA | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.18 | 104.5K | 25,000 | D | ↗ |
| 2025-06-26 | CHOLMONDELEY PAULA H | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.18 | 104.5K | 25,000 | D | ↗ |
| 2025-06-26 | Altschuler Steven | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.18 | 104.5K | 25,000 | D | ↗ |
| 2025-06-26 | Agger Mette Kirstine | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.18 | 104.5K | 25,000 | D | ↗ |
| 2025-05-16 | Townsend Richard Nolan | Director / Officer | S-Sale | D | Common Stock | 1,074 | 2.77 | 3.0K | 221,173 | D | ↗ |
| 2025-05-16 | See Tai Sandi | Officer | S-Sale | D | Common Stock | 367 | 2.77 | 1.0K | 59,242 | D | ↗ |
| 2025-05-16 | Robertson Jenny | Officer | S-Sale | D | Common Stock | 521 | 2.77 | 1.4K | 63,098 | D | ↗ |
| 2025-05-16 | Adler Eric | Officer | S-Sale | D | Common Stock | 585 | 2.77 | 1.6K | 67,681 | D | ↗ |
| 2025-03-14 | Townsend Richard Nolan | Director / Officer | A-Award | A | Common Stock | 2,128 | 2.61 | 5.6K | 222,247 | D | ↗ |
| 2025-03-14 | See Tai Sandi | Officer | A-Award | A | Common Stock | 5,720 | 2.61 | 14.9K | 59,609 | D | ↗ |
| 2025-03-14 | Robertson Jenny | Officer | A-Award | A | Common Stock | 5,720 | 2.61 | 14.9K | 63,619 | D | ↗ |
| 2025-03-14 | Otero Jose Manuel | Officer | A-Award | A | Common Stock | 5,720 | 2.61 | 14.9K | 63,220 | D | ↗ |
| 2025-02-19 | Townsend Richard Nolan | Director / Officer | S-Sale | D | Common Stock | 4,326 | 4.41 | 19.1K | 220,119 | D | ↗ |
| 2025-02-19 | See Tai Sandi | Officer | S-Sale | D | Common Stock | 1,486 | 4.41 | 6.6K | 53,889 | D | ↗ |
| 2025-02-19 | Robertson Jenny | Officer | S-Sale | D | Common Stock | 2,101 | 4.41 | 9.3K | 57,899 | D | ↗ |
| 2025-02-19 | Adler Eric | Officer | S-Sale | D | Common Stock | 2,359 | 4.41 | 10.4K | 68,266 | D | ↗ |
| 2025-01-17 | Rasbach Kyle | Officer | A-Award | A | Stock Option (right to buy) | 245,250 | 5.07 | 1.24M | 245,250 | D | ↗ |
| 2025-01-07 | Townsend Richard Nolan | Director / Officer | A-Award | A | Stock Option (right to buy) | 207,500 | 7.33 | 1.52M | 207,500 | D | ↗ |
| 2025-01-07 | See Tai Sandi | Officer | A-Award | A | Common Stock | 38,750 | 0.00 | — | 55,375 | D | ↗ |
| 2025-01-07 | Robertson Jenny | Officer | A-Award | A | Common Stock | 36,250 | 0.00 | — | 60,000 | D | ↗ |
| 2025-01-07 | Otero Jose Manuel | Officer | A-Award | A | Common Stock | 26,250 | 0.00 | — | 57,500 | D | ↗ |
| 2025-01-07 | Adler Eric | Officer | A-Award | A | Common Stock | 43,750 | 0.00 | — | 70,625 | D | ↗ |
| 2024-12-18 | Rasbach Kyle | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-10 | Townsend Richard Nolan | Director / Officer | M-Exempt | A | Common Stock | 2,500 | 2.33 | 5.8K | 123,195 | D | ↗ |
| 2024-11-25 | CHOLMONDELEY PAULA H | Director | P-Purchase | A | Common Stock | 15,000 | 6.99 | 104.9K | 30,627 | D | ↗ |
| 2024-11-11 | Townsend Richard Nolan | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 2,500 | 2.33 | 5.8K | 121,155 | D | ↗ |
| 2024-11-11 | Tanguler Tolga | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-10 | Townsend Richard Nolan | Director / Officer | M-Exempt | A | Common Stock | 5,000 | 2.33 | 11.7K | 125,695 | D | ↗ |
| 2024-09-10 | Townsend Richard Nolan | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 5,000 | 2.33 | 11.7K | 128,655 | — | ↗ |
| 2023-11-07 | Omega Fund VI, L.P. | 10% Owner | C-Conversion | A | Common Stock | 1,415,865 | 0.00 | — | 1,415,865 | — | ↗ |
| 2023-11-07 | Longitude Capital Partners IV, LLC | 10% Owner | P-Purchase | A | Common Stock | 454,545 | 11.00 | 5.00M | 2,567,100 | — | ↗ |
| 2023-11-02 | Omega Fund VI, L.P. | 10% Owner | — | D | Series A convertible preferred stock | 1,415,865 | 0.00 | — | 0 | — | ↗ |
| 2023-11-02 | Longitude Capital Partners IV, LLC | 10% Owner | — | I | Series B convertible preferred stock | 274,314 | 0.00 | — | 0 | — | ↗ |
| 2023-11-02 | DIAZ REINALDO M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-02 | CHOLMONDELEY PAULA H | Director | — | D | Stock Option (right to buy) | 44,184 | 11.02 | 486.9K | 0 | — | ↗ |
| 2023-11-02 | Altschuler Steven | Director | — | D | Stock Option (right to buy) | 112,240 | 2.33 | 261.5K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
74.09M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | R. Nolan Townsend Chief Executive Officer and Director | 632.7K | — | 1.49M | 1.17M | 348.0K | 10.8K | 3.65M | 72.84% | ↗ |
| 2 | 2025 | Jenny R. Robertson, J.D. Former Chief Legal Officer | 459.6K | — | 485.6K | 407.4K | 183.8K | 609.4K | 2.15M | 41.62% | ↗ |
| 3 | 2025 | Louis Tamayo Chief Financial Officer | 181.8K | — | 215.6K | 1.07M | 197.8K | 4.8K | 1.67M | 76.93% | ↗ |
| 4 | 2024 | R. Nolan Townsend Chief Executive Officer and Director | 600.0K | — | 633.5K | 2.83M | 297.0K | 11.0K | 4.38M | 79.25% | ↗ |
| 5 | 2024 | Jose Manuel Otero, Ph.D. Chief Technical Officer | 268.9K | — | 568.4K | 2.55M | 165.3K | 7.6K | 3.56M | 87.58% | ↗ |
| 6 | 2024 | Eric Adler, M.D. Chief Medical Officer and Head of Research | 468.9K | — | 456.9K | 2.04M | 171.0K | 21.5K | 3.16M | 79.09% | ↗ |
| 7 | 2024 | Jenny R. Robertson, J.D. Former Chief Legal Officer | 436.5K | — | 343.9K | 1.53M | 160.6K | 11.9K | 2.49M | 75.49% | ↗ |
| 8 | 2023 | Micah Zajic Former Chief Financial Officer | 423.2K | 166.0K | — | 2.46M | — | 11.1K | 3.06M | 80.41% | ↗ |
| 9 | 2023 | Eric Adler, M.D. Chief Medical Officer and Head of Research | 296.5K | 234.8K | — | 2.42M | 80.8K | 11.4K | 3.04M | 79.51% | ↗ |
| 10 | 2023 | R. Nolan Townsend Chief Executive Officer and Director | 508.0K | — | — | 872.9K | 347.9K | 8.5K | 1.74M | 50.25% | ↗ |
| 11 | 2023 | Jenny R. Robertson, J.D. Chief Business and Legal Officer | 402.5K | — | — | 678.7K | 204.0K | 11.4K | 1.30M | 52.35% | ↗ |
| 12 | 2022 | Jenny R. Robertson, J.D. Chief Business and Legal Officer | 257.8K | 99.0K | — | 691.0K | 14.9K | 2.6K | 1.07M | 64.87% | ↗ |
| 13 | 2022 | R. Nolan Townsend Chief Executive Officer and Director | 465.0K | — | — | — | 186.0K | 54.4K | 705.4K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jose Manuel Otero | Chief Operating Officer | 3M | — |
| Eric Adler | Advisor | 3M | — |
| R. Nolan Townsend | Chief Executive Officer & Director | 991.5K | male |
| Louis Tamayo | Chief Financial Officer & Principal Accounting Officer | 638.9K | male |
| Jenny R. Robertson | Chief Legal Officer | 617.9K | female |
| Jordan Baumhardt | Vice President of Corporate Development | — | male |
| Narinder Bhalla FACC FSCAI | Chief Medical Officer | — | — |
| Leslie DiRisio | Senior Vice President of Development Operations | — | female |
| Ronald G. Crystal | Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board | — | — |
| Ryan McHenry | Vice President & Corporate Controller | — | male |
| Sandi See Tai | Chief Development Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LXEO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
